Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,268 | 1,034 | 1,070 | -247 | -154 |
| Depreciation Amortization | 39 | 25 | 13 | 53 | 31 |
| Accounts receivable | 849 | 968 | 164 | 10 | -4 |
| Accounts payable and accrued liabilities | -1,877 | -2,383 | -1,471 | -31 | -36 |
| Other Working Capital | -991 | -1,495 | -1,350 | -24 | -36 |
| Other Operating Activity | 332 | 715 | 597 | 21 | 40 |
| Operating Cash Flow | $-380 | $-1,135 | $-977 | $-217 | $-159 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 1,468 | 1,468 | 1,468 | -13 | -6 |
| Net Acquisitions | 346 | 346 | 346 | N/A | N/A |
| Purchase Of Investment | -108 | -109 | -102 | N/A | N/A |
| Sale Of Investment | 26 | 26 | N/A | N/A | N/A |
| Other Investing Activity | 5 | 2 | 0 | 0 | 0 |
| Investing Cash Flow | $1,737 | $1,732 | $1,712 | $-13 | $-6 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -7 | -9 | -6 | -17 | -14 |
| Common Stock Issued | N/A | N/A | N/A | -163 | -93 |
| Other Financing Activity | 0 | 0 | 0 | -1 | -1 |
| Financing Cash Flow | $-7 | $-9 | $-6 | $-181 | $-107 |
| Exchange Rate Effect | -19 | -160 | -191 | 10 | -11 |
| Beginning Cash Position | 859 | 859 | 859 | 1,260 | 1,260 |
| End Cash Position | 2,190 | 1,287 | 1,397 | 859 | 977 |
| Net Cash Flow | $1,331 | $428 | $538 | $-401 | $-283 |
| Free Cash Flow | |||||
| Operating Cash Flow | -380 | -1,135 | -977 | -217 | -159 |
| Capital Expenditure | 0 | 0 | 0 | -13 | -6 |
| Free Cash Flow | -380 | -1,135 | -978 | -230 | -165 |